CRDF
Closed
Cardiff Oncology Inc
3.51
+0.36 (+11.43%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 3.15
Day's Range: 3.07 - 3.695
Send
sign up or login to leave a comment!
When Written:
1.65
Cardiff Oncology Inc is a clinical-stage biotechnology company that focuses on developing cancer treatments. The company's lead drug candidate, onvansertib, is a small molecule inhibitor of the polo-like kinase 1 (PLK1) enzyme, which plays a critical role in cell division and is overexpressed in many types of cancer. Onvansertib is currently being evaluated in clinical trials for the treatment of acute myeloid leukemia (AML), metastatic castration-resistant prostate cancer (mCRPC), and advanced solid tumors. Cardiff Oncology also has a portfolio of preclinical drug candidates targeting other key cancer pathways. The company is headquartered in San Diego, California, and was founded in 2015.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








